Bivalirudin

BIVALIRUDIN- bivalirudin injection, powder, lyophilized, for solution
Sandoz Inc

1 INDICATIONS AND USAGE

Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

Bivalirudin has been studied only in patients receiving concomitant aspirin.

The recommended dose of bivalirudin is an intravenous bolus dose of 0.75 mg/kg, followed immediately by an infusion of 1.75 mg/kg/h for the duration of the procedure. Five minutes after the bolus dose has been administered, an activated clotting time (ACT) should be performed and an additional bolus of 0.3 mg/kg should be given if needed.

Extended duration of infusion following PCI at 1.75 mg/kg/h for up to 4 hours post-procedure should be considered in patients with ST segment elevation MI (STEMI).

2.2 Dose Adjustment in Renal Impairment

Bolus Dose

No reduction in the bolus dose is needed for any degree of renal impairment.

Maintenance Infusion

In patients with creatinine clearance less than 30mL/min (by Cockcroft Gault equation), reduce the infusion rate to 1 mg/kg/h. Monitor anticoagulant status in patients with renal impairment.

In patients on hemodialysis, reduce the infusion rate to 0.25 mg/kg/h [see Use in Specific Populations ( 8.6) , Clinical Pharmacology ( 12.3)].

2.3 Instructions for Preparation and Administration

Bivalirudin is intended for intravenous bolus injection and continuous infusion after reconstitution and dilution.

Preparation Instructions for Bolus Injection and Continuous Infusion

To each 250 mg vial, add 5 mL of Sterile Water for Injection, USP.
Gently swirl until all material is dissolved.
Withdraw and discard 5 mL from a 50 mL infusion bag containing 5% Dextrose in Water or 0.9% Sodium Chloride for Injection.
Add the contents of the reconstituted vial to the infusion bag containing 5% Dextrose in Water or 0.9% Sodium Chloride for Injection to yield a final concentration of 5 mg/mL (e.g., 1 vial in 50 mL; 2 vials in 100 mL; 5 vials in 250 mL).
Adjust the dose to be administered according to the patient’s weight (see Table 1).
Table 1: Dosing Table

Weight
(kg)

Using 5 mg/mL
Concentration

Bolus
0.75 mg/kg
(mL)

Infusion
1.75 mg/kg/h
(mL/h)

43-47

7

16

48-52

7.5

17.5

53-57

8

19

58-62

9

21

63-67

10

23

68-72

10.5

24.5

73-77

11

26

78-82

12

28

83-87

13

30

88-92

13.5

31.5

93-97

14

33

98-102

15

35

103-107

16

37

108-112

16.5

38.5

113-117

17

40

118-122

18

42

123-127

19

44

128-132

19.5

45.5

133-137

20

47

138-142

21

49

143-147

22

51

148-152

22.5

52.5

Drug Compatibilities

No incompatibilities have been observed with administration sets.

Do not administer the drugs listed in Table 2 in the same intravenous line with bivalirudin.

Table 2: Drugs Not for Administration in the Same Intravenous Line with Bivalirudin
Alteplase
Amiodarone HCl
Amphotericin B
Chlorpromazine HCl
Diazepam
Dobutamine
Prochlorperazine Edisylate
Reteplase
Streptokinase
Vancomycin HCl

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Preparations of bivalirudin containing particulate matter should not be used. Reconstituted material will be a clear to slightly opalescent, colorless to slightly yellow solution.

Page 1 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.